Analysis of the Regulatory Requirements for Biosimilars in the EU
2 Angebote vergleichen
Bester Preis: € 21,95 (vom 03.07.2016)1
Symbolbild
Analysis of the Regulatory Requirements for Biosimilars in the EU
DE PB NWISBN: 9783639888812 bzw. 3639888812, in Deutsch, Av Akademikerverlag, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, buecher.de GmbH & Co. KG, [1].
A biosimilar is a biological medicinal product which is a copy of an original (innovator) product. The innovator product is often manufactured by a different company and after the patent of the innovator product expires a biosimilar can be registered in the European Union to a lower price than the innovator product. The first biosimilar in the European Union was registered in 2006 and was a Somatropin compound. Now are about 20 biosimilars registered in the European Union. Forecasts expect that there will be a huge amount of biosimilars pushing on the market in the near future and that will have a big influence on the industry. 2016. 68 S. 220 mm Versandfertig in 6-10 Tagen, Softcover, Neuware.
Von Händler/Antiquariat, buecher.de GmbH & Co. KG, [1].
A biosimilar is a biological medicinal product which is a copy of an original (innovator) product. The innovator product is often manufactured by a different company and after the patent of the innovator product expires a biosimilar can be registered in the European Union to a lower price than the innovator product. The first biosimilar in the European Union was registered in 2006 and was a Somatropin compound. Now are about 20 biosimilars registered in the European Union. Forecasts expect that there will be a huge amount of biosimilars pushing on the market in the near future and that will have a big influence on the industry. 2016. 68 S. 220 mm Versandfertig in 6-10 Tagen, Softcover, Neuware.
2
Analysis of the Regulatory Requirements for Biosimilars in the EU
EN NWISBN: 9783639888812 bzw. 3639888812, in Englisch, VDM Verlag Dr. Müller, Saarbrücken, Deutschland, neu.
Lieferung aus: Deutschland, Versandfertig in 2 - 3 Tagen.
A General Overview, A biosimilar is a biological medicinal product which is a copy of an original (innovator) product. The innovator product is often manufactured by a different company and after the patent of the innovator product expires a biosimilar can be registered in the European Union to a lower price than the innovator product. The first biosimilar in the European Union was registered in 2006 and was a Somatropin compound. Now are about 20 biosimilars registered in the European Union. Forecasts expect that there will be a huge amount of biosimilars pushing on the market in the near future and that will have a big influence on the industry.
A General Overview, A biosimilar is a biological medicinal product which is a copy of an original (innovator) product. The innovator product is often manufactured by a different company and after the patent of the innovator product expires a biosimilar can be registered in the European Union to a lower price than the innovator product. The first biosimilar in the European Union was registered in 2006 and was a Somatropin compound. Now are about 20 biosimilars registered in the European Union. Forecasts expect that there will be a huge amount of biosimilars pushing on the market in the near future and that will have a big influence on the industry.
Lade…